Anti Park in Son MODELS

download Anti Park in Son MODELS

of 23

Transcript of Anti Park in Son MODELS

  • 7/31/2019 Anti Park in Son MODELS

    1/23

    UNDER GUIDANCE OF Mr. S.B.KASTURE

    PRESENTED BY- SHAIKH ARIF H.

    (FIRST SEMISTER M.PHARM

    PHARMACOLOGY)

    SANJIVANI COLLEGE OF PHARMACEUTICAL EDUCATION & RESEARCH

    (KOPARGAON)

    PARKINSONS DISEASE

  • 7/31/2019 Anti Park in Son MODELS

    2/23

    Definition.

    Dopamine synthesis.

    Models.

    In Vitro Models.

    In Vivo Models.

    References.

    2

  • 7/31/2019 Anti Park in Son MODELS

    3/23

    Parkinsons disease is a degenerative disorder

    of CNS comprising four cardinal feature:

    Tremor

    Rigidity,

    Akinesia,

    Postural instability (TRAP)

    3

  • 7/31/2019 Anti Park in Son MODELS

    4/23

    NORMAL PARKINSONS DISEASE

    4

  • 7/31/2019 Anti Park in Son MODELS

    5/23

    5

  • 7/31/2019 Anti Park in Son MODELS

    6/23

    Definite: Old age.

    Probable: Positive family history.

    Possible: Herbicides, pesticides, heavy metals,

    proximity to industry, rural residence, well water,

    repeated head trauma, etc.

    6

  • 7/31/2019 Anti Park in Son MODELS

    7/23

    Models are required for screening the Anti PD

    Drug.

    Models are the replica of the disease state in

    human i.e. models are the replica of the diseasedhuman.

    Models can help observe the biochemical

    changes causing the disease or caused by the

    disease.

    7

  • 7/31/2019 Anti Park in Son MODELS

    8/23

    The In Vitro Models include the following:

    Culture of Substantia Nigra.

    Inhibition of Apoptosis in Neuroblastoma SH-

    SY5Y cells.

    8

  • 7/31/2019 Anti Park in Son MODELS

    9/23

    The In Vivo models includes the following:

    Tremorine & Oxotremorine antagonism.

    MPTP models for PD.

    Reserpine antagonism.

    Elevated body swing test.

    9

  • 7/31/2019 Anti Park in Son MODELS

    10/23

    Purpose & Rationale:

    The muscarinic agonists

    tremorine and oxotremorine induce parkinsonism-like signs such as tremor, ataxia, spasticity, salivation,

    lacrimation and hypothermia. These signs are

    antagonized by anticholinergic drugs.

    10

  • 7/31/2019 Anti Park in Son MODELS

    11/2311

    6-10 NMRI mice weighing 18-22gm are used.

    They are dosed orally with the

    standard (5mg/kg

    Benzatropine mesilate) & testcompound 1 hr. prior to

    administration of 0.5mg/kg

    Oxotremorine s.c.

    Rectal temp. is measured

    before administration of the

    compound(Basal value) & 1, 2 &

    3 hr. after oxotremorine

    injection.

    Tremor is scored after

    oxotremorine dosage in 10-s

    observation periods every

    15min for 1 h.

    Salivation and lacrimation are

    scored 15 and 30min after

    oxotremorine injection.

  • 7/31/2019 Anti Park in Son MODELS

    12/23

    12

    Absent 0

    Slight 1

    Medium 2

    Severe 3

  • 7/31/2019 Anti Park in Son MODELS

    13/23

    Hypothermia:

    The differences of body temperatureafter 1, 2 and 3 hr versus basal values aresummarized for each animal in the control groupand the test groups. The average values are

    compared statistically. Tremor:

    The scores for all animals in each group atthe three observation periods are summarized.

    The numbers in the treated groups are expressedas percentage of the number of the controlgroup.

    13

  • 7/31/2019 Anti Park in Son MODELS

    14/23

    Salivation and Lacrimation

    The scores for both symptoms for all animals in eachgroup are summarized at the two observation periods.

    The numbers in the treated groups are expressed as a

    percentage of the number of the control group.

    14

  • 7/31/2019 Anti Park in Son MODELS

    15/23

    PURPOSE AND RATIONALE

    MPTP (N-methyl-4-phenyl-1,2,3,6tetrahydropyridine)

    has been shown to cause symptoms of Parkinsonsdisease in exposed individuals.

    15

  • 7/31/2019 Anti Park in Son MODELS

    16/23

    8 adult rhesus monkeys

    weighing 5-8kg were

    treated with MPTP (10-

    18mg/kg, i.v.) over a

    period of 5-8 days.

    The animals showed a

    Parkinsons like disorder

    which was reveresed by

    L-Dopa administration.

    The pathological &

    biochemical changes

    produced by MPTP were

    similar to the patient with

    PD.

    16

  • 7/31/2019 Anti Park in Son MODELS

    17/23

    The severity of parkinson symptoms is rated by trained

    observers using a scale of 0 (normal) to 17 (maximumseverity) that assesses:

    Movement (0: normal;1: reduced; 2: sleepy),

    Checking movements (0: present; 1: reduced; 2: absent),

    Attention and blinking (0: normal; 1: abnormal), Posture (0: normal; 1: abnormal trunk; 2: abnormal trunk

    and tail; 3: abnormal trunk, tail, and limbs; 4: flexedposture),

    Balance and coordination (0: normal; 1: impaired; 2:

    unstable; 4: falls),

    Reactions (0: normal; 1: reduced; 2: slow; 3: absent)

    Vocalizations (0: normal; 1: reduced; 2: absent).

    17

  • 7/31/2019 Anti Park in Son MODELS

    18/23

    PURPOSE AND RATIONALE:

    Reserpine induces depletion of central

    catecholamine stores.

    18

  • 7/31/2019 Anti Park in Son MODELS

    19/23

    Male NMRI mice

    weighing 20-25 gm

    are injected by

    Reserpine (5mg/kg,

    i.p.) before 24 hr of

    expt.

    The test compound is

    injected 30 minute

    prior to observation.

    The animals are placed

    singly onto the floor of

    a Perspex container(30

    26 cm, 20 cm high),

    situated on a Panlab

    proximity sensor unit.

    Horizontal

    movements are

    recorded for 10 min.

    Rearings andgrooming episodes

    are recorded by an

    experienced observer.

    19

  • 7/31/2019 Anti Park in Son MODELS

    20/23

    Locomotor activity and grooming scores

    of drug treated animals are compared

    with controls treated with reserpine and

    vehicle only by analysis of variance.

    20

  • 7/31/2019 Anti Park in Son MODELS

    21/23

    1. Goodman & Gilmons, The Pharmacological Basis Of

    Therapeutics. By Laurence L. Brunton, John S. Lazo. Keith L.

    Parker, 11th edition;934-961

    H. Gerhard Vogel(Ed.), 2008; Second Edition, DrugDiscovery and Evaluation Pharmacological Assays,Springer Publication Page : 820-822, 824-829.

    K. D. Tripathi,2009; Sixth Edition, Essentials of Medical

    Pharmacology. Jaypee Brothers Medical Publishers,Page : 416.

    21

  • 7/31/2019 Anti Park in Son MODELS

    22/23

    22

  • 7/31/2019 Anti Park in Son MODELS

    23/23